Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC37,70,71”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“Several mechanisms of resistance to antiangiogenic therapy have been proposed thus far (9, 33).”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840 · cited 1×
“Total collagen content was determined by measuring hydroxyproline content of the hydrolysate samples (76).”
MethodDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Research works printed but not linked: 1
- 10.1056/NEJM198612253152606 · DOI · Paper page
Cited by
Items 201–258 of 258
Villanueva, M. T. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.127 · Cited by 3
Normalization of the tumor vasculature
Klein, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816196-8.00015-1 · Cited by 3
Prognostic value of disease-free interval in colorectal cancer: Is it time?
Birgin, E., Doyon, F., Burkert, J., Téoule, P., Rasbach, E., Rahbari, M., Reißfelder, C., Betzler, A. M., & Rahbari, N. N. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.06.001 · Cited by 3
Self-citationGao, M., Ye, P., Zhang, Y., Guo, Y., & Xu, J. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf019 · Cited by 4
“The stiffened matrix forms a physical barrier against the penetration of drugs, and the study has shown that decreasing the deposited HA in the ECM benefited anti-VEGF therapy in colorectal cancer patients with liver metastasis (27).”
Estabillo, L. L., Skaga, E., Halldórsson, S., Vik-Mo, E. O., & Sandberg, C. J. (2025) · BMC Cancer · doi:10.1186/s12885-025-15163-z · Cited by 5
“Multiple studies across various cancers have already shown enhanced treatment efficacy by targeting ECM components [57, 58], ABC drug efflux pumps [59, 60], stemness-related pathways such as Notch, Wnt, and Hedgehog [61], as well as epigenetic neural remodeling [52, 62], potentially informing novel…”
Liu, W., Xu, W., Liu, W., Liang, R., Tang, S., Luo, X., Liu, C., Liao, Q., Sun, H., Wang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738966 · Cited by 4
“Excessive HA exacerbates hypoxia, impairs immune cell in fi ltration, increases interstitial pressure, and compresses blood vessels (76).”
Self-citationMechanobiology of solid tumor vasculature: implications for tumor progression
Kondapaneni, R. V., Libring, S., Dsa, S., & Reinhart‐King, C. A. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10345-y · Cited by 2
“For example, when tumor stiffness was targeted with anti-RAS drugs or with polyethylene glycol-conjugated (PEGylated) hyaluronidase concurrently with anti-VEGF therapy (bevacizumab), efficacy of the anti-VEGF treatment or anti-VEGF-chemotherapeutic combination treatment improved [53, 54].”
A Basic and Clinical Perspective on the Future of Perioperative Therapy for Gastric Cancer
Chen, J., Duda, D. G., Matsui, A., Kikuchi, H., Kawakubo, K., & Kitahara, S. (2019) · Surgery Gastroenterology and Oncology · doi:10.21614/sgo-24-6-273 · Cited by 2
Self-citationFu, R., & Hong, X. (2022) · BioMed Research International · doi:10.1155/2022/3113857 · Cited by 2
“In an anti-VEGF therapy of colorectal cancer, ECM is remodeled and treatment e ffi cacy is improved in mouse models [35].”
RetractedLiu, S., Gu, Y., Shi, Y., Yu, S., Li, W., & Lv, W. (2024) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15959 · Cited by 2
Guo, K.-C., Wang, Z., & Su, X. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-4115-8 · Cited by 3
Zhou, H., Yang, X., Yang, Q., Cai, Z., Hu, K., & Huang, T. (2024) · Medicine · doi:10.1097/md.0000000000040230 · Cited by 4
“[12] Contrarily, additional research has identified a favorable association between levels of macrophage colony-stimulating factor (M-CSF) and the survival rate among patients with CRC. [13] This implies that M-CSF may enhance phagocytosis through the modulation of cytokine secretion and other…”
BackgroundMicrofluidic Models of the Tumor Microenvironment
Chang, C.-S., Holter, J. C., & Song, J. W. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00252 · Cited by 2
Shen, C., Bi, Y., Chai, W., Zhang, Z., Yang, S., Liu, Y., Wu, Z., Peng, F., Fan, Z., & Hu, H. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01678-6 · Cited by 1
“ECM in colorectal cancer promotes epithelial-mesenchymal transformation of cancer cells [29].”
BackgroundLi, M., Gao, N., Xu, L., Ge, P., Jiang, N., & Shang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1646473 · Cited by 1
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1
Self-citationLiang, D., Xue, F., Xie, J., Yang, J., Ni, X., Zhang, J., & Gu, H. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01534-x · Cited by 1
“An experimental liver metastasis model was induced, as previously reported [15].”
Jiang, L., Xu, S., Peng, J., Jing, Y., Wu, H., Wu, W., 黄志纯, Pan, J., & Tan, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-48018-z · Cited by 1
“The down-regulation of ECM in colorectal cancer can promote the EMT process of cancer cells, leading to liver metastasis 33 .”
Li, L., Jiang, Z., Wang, S. S., Yu, P., Dong, J., Liu, J. H., Xue, Z., Wang, Y., Yang, Z., & Yang, Y. (2026) · Food Chemistry · doi:10.1016/j.foodchem.2026.150305 · Cited by 1
Extracellular matrix stiffness and mechanotransduction in cancer drug resistance
Song, Y., Huang, C., Han, J., Wang, S., Liu, H., Li, Y., Jiang, Z., Tan, X., Wu, T., & Jiang, F. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101470 · Cited by 1
Self-citationTherapy for colorectal cancer liver metastases: understanding resistance
Ray, K. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.183 · Cited by 1
Radiation Therapy-Induced Metastasis Promotes Secondary Malignancy in Cancer Patients
O’Malley, J., Inigo, J. R., Gokhale, A., Betapudi, V., Kumar, R., & Chandra, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65171-1 · Cited by 1
Siegel, P. M., Nyström, H., & Brodt, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91706-3.00011-4 · Cited by 1
Challenges to addressing the unmet medical needs for immunotherapy targeting cold colorectal cancer
Jeong, K. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.215 · Cited by 2
Liu, T., Liu, J., Chen, Q., Wu, L., Zhang, L., Qiao, D., Huang, Z., Lu, T., Hu, A., & Wang, J. (2024) · Medicine · doi:10.1097/md.0000000000039854 · Cited by 1
“[16] Our study identified 2 ECM subgroups based on consensus clustering of genes involved in ECM receptor interaction pathways.”
BackgroundQiao, T., Guo, W., Meng, F., Zhou, Y., Xiong, Y., Feng, Y., Zhang, C., Wu, Y., Zhao, J., Jiang, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-152456/v1 · Cited by 1
“This reduces the supply of oxygen and nutrients, resulting in a microenvironment with high osmotic, hypoxic, acidic, and interstitial pressure [12].”
BackgroundJahangiri, A., Chen, W. C., Chandra, A., Nguyen, A. T., Yagnik, G., Weiss, J., Wolf, K. J., Lin, J.-M. G., Mueller, S., Rick, J. W., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/272328
“matrix of bevacizumab-resistant tumors (17).”
Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies
Bhaskar, L. V., & Saikrishna, L. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_14
Li, J., Han, T., Wang, X., Wang, Y., & Yang, Q. (2020) · doi:10.21203/rs.3.rs-111313/v1
“Page 9/21 therapeutic targets for reducing physical barriers to systemic treatments in patients with mCRC who receive anti-VEGF therapy [44].”
BackgroundLi, H., Zong, S., Wen, Y., Du, P., Yu, W., Wu, N., Zong, G., & Xiao, H. (2020) · doi:10.21203/rs.3.rs-135813/v1
Bioinformatics analysis of aberrantly methylated- differentially expressed genes in gastric cancerPreprint
Siyuan, S., & Shu, P. (2021) · Research Square · doi:10.21203/rs.3.rs-400315/v1
“The ECM-receptor interaction plays a crucial role in many cancers [36, 37].”
BackgroundHuang, C., He, J., Dong, Y. W., Chen, Y., Peng, A., & Huang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-531467/v1
Ren, T., Jia, H., Wu, Q. D., Zhang, Y., Ma, Q., Dong, Y., Gao, X., Xie, D., Xu, Z., Zhang, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-830539/v1
Xu, Y., Gao, Y., Qian, L., Feng, W., Song, T., Li, Y., Guo, F., Zheng, J., Li, Y., Zhang, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-946298/v1
Faculty Opinions recommendation of Physical traits of cancer.
Tanner, K. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738942894.793586837
Xiang, H., Wang, Z., Shen, X., Chen, E., Chen, W., & Song, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-966708/v1
ECM-derived biophysical cues mediate interstitial flow-induced sprouting angiogenesisPreprint
Chang, C.-W., Shih, H.-C., Cortes-Medina, M. G., Beshay, P. E., Avendano, A., Seibel, A. J., Liao, W., Tung, Y., & Song, J. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.04.494804
Su, Y., Luo, B., Lu, Y., Wang, D., Yan, J., Zheng, J., Xiao, J., Wang, Y., Xue, Z., Yin, J., et al. (2023) · doi:10.1158/1078-0432.c.6531219.v1
Yin, D., Sun, Q., Li, Y., Shen, W. H., Shang, W., Xu, Y., Yang, J., Chen, J., Gao, W., Wu, Q., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3259314/v1
CD44 Might Promote the Migration and Invasion of Ovarian Cancer by Regulating CD36Preprint
Gao, Y., Shi, R., Dong, J., Feng, W., Dang, Y., Song, T., Li, Y., Guo, F., Jiao, Z., Yu, L., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4645301
Kopyeva, I., Goldner, E. C., Hoye, J. W., Yang, S., Regier, M. C., Vera, K. R., Bretherton, R. C., & DeForest, C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.04.588191
Sinusoidal cells in liver metastasis
Kawada, N., Sato-Matsubara, M., Hoang, T. H., & Enomoto, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00018-8
Unravelling the in vivo traits of vasculogenic mimicry
Oraiopoulou, M., Lefebvre, T. L., Tzamali, E., Else, T. R., Cannell, I. G., Wright, L. C., Bunce, E. V., Brodie, C. R., Sweeney, P. W., Porcu, L., et al. (2026) · Theranostics · doi:10.7150/thno.140146
“As the field turns towards vasculature normalisation to facilitate chemotherapy delivery and radiotherapy response [19] defining the in vivo phenotype of VM becomes essential for predicting response and stratifying patients.”
Angiogenesis and Microvascular Remodeling
Chappell, J. C. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_3
Tian, X., Lin, R., Bao, J., Pan, Y., Liu, J., Zhou, H., Qu, H., Hu, D., & Wang, N. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07085-y
Lee, Y. C., Burgos, B. A., Green, N. H., Claeyssens, F., & English, W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.09.687017
“In colorectal cancer liver metastases, inhibition of VEGF receptor signaling leads to the accumulation of hyaluronic acid and sulfated glycosaminoglycans, increasing tissue stiffness [67].”
Jurj, A., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Figshare · doi:10.6084/m9.figshare.21151438
Wen, J., He, Y., Li, K., Li, R., & Zhang, C. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2681-2278
Wang, C., Qian, S., Li, W., Zhou, L., Chen, L., Meng, J., Jiang, R., Niu, B., Sun, K., Ding, Z., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10004-6 · Cited by 1
“Besides,softeningtheECMthroughhyaluronic acid depletion could also improve perfusion of liver metastatic colorectal cancer and systemic chemotherapy response in mice 15 .”
Rethinking residual p53 function in HPV-positive cervical cancer cells
Farrukh, S., Kavčič, N., Canarutto, G., Piazza, S., & Banks, L. (2026) · Journal of Virology · doi:10.1128/jvi.00479-25
“The role of ECM has been proven in several cancers: it has been shown to be increased in breast cancers (37), while the upregulation of ECM-receptor interactions can cause EMT in colorectal cancer cells (38), and can lead to metastasis in gastric cancer (39).”
Liu, C., Zhou, R., Liu, W., Li, R., Xiao, J., Wu, J., Ning, Z., Chen, Z., Qian, C., Zhang, Y., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.011
“A low dose of bevacizumab could induce tumor vessel normalization (TVN), reduce hypoxia, and potentiate cancer immunotherapy 14,15 .”
Yang, H., Wu, S., & Chen, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1855761 · Cited by 2
Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion
Maqbool, M., Surendranath, A., Baba, S. K., Jawwad, T., Elfaki, I., Mir, R., Kumar, R., Shahab Uddin, M. S., Haris, M., Macha, M. A., et al. (2026) · 癌症:英文版 · doi:10.34133/cancomm.0045
Engineering Biomimetic Tumor Organoids Inspired by Janus Stiffness–Driven Cell Stemness
Zhu, Z., Zhou, S., Gu, T., Liu, Y., Xing, K., Gong, J., Siow, L., Jiang, Y., Ye, X., Lu, K., et al. (2026) · Small · doi:10.1002/smll.75385
Xie, C., Zhu, H., Wen, J., Mo, Y., Wang, W., Chan, C. Y., Lin, X., Huang, X., Li, G., Wu, Y., et al. (2026) · Advanced Materials · doi:10.1002/adma.202523468 · Cited by 1
Zaman, M., NAZARE, T., Sarkar, A., & Mirzapourshafiyi, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124696
Metadata
- Authors
- Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., Heishi, T., Martin, J. D., Huang, Y., Maimon, N., Reissfelder, C., Weitz, J., Boucher, Y., Clark, J. W., Grodzinsky, A. J., Duda, D. G., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- University Hospital Carl Gustav Carus (DE)
- Department of General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany.
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- Fukumura, Dai
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-10-12
- Volume
- 8
- Issue
- 360
- Pages
- 360ra135-360ra135
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5457741
- OpenAlex
- W2530012709
- Cited by
- 258
- References
- 78
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 24 · 2023: 28 · 2022: 37 · 2021: 40 · 2020: 30 · 2019: 21 · 2018: 19 · 2017: 16 · 2016: 3
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- NIH (CA080124, T32DK007191, CA126642, CA197743, CA096915, CA139168, CA159258, CA098706, CA173518)
- American Cancer Society (120733-RSG-11-073-01-TBG)
- German Research Foundation
- Foundation for Science and Technology
- Portuguese Human Potential Operational Program/European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anti-VEGF therapy, colorectal liver metastases, extracellular matrix remodeling, hyaluronic acid, sulfated glycosaminoglycans, tumor stiffness, tumor hypoxia, bevacizumab, acquired drug resistance, tumor perfusion, combination chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Animals, Hypoxia, Biomechanical Phenomena, Extracellular Matrix, Glycosaminoglycans, Humans, Hyaluronic Acid, Liver Neoplasms, Mice, Inbred BALB C, Mice, Inbred C57BL, Colorectal Neoplasms, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.